Rationale for revascularization to improve prognosis in stable coronary artery disease: the data from ISCHEMIA trial
https://doi.org/10.15829/1560-4071-2020-3819
Abstract
Although myocardial revascularization is one of the most studied types of medical interventions, there is a heated discussion in cardiology about the feasibility and indications for it in patients with stable coronary artery disease (chronic coronary syndrome). The recently completed ISCHEMIA trial is the largest current study comparing conservative versus invasive strategies in this category of patients. The article discusses the rationale for revascularization to improve prognosis according to the ISCHEMIA trial.
Supporting agencies: Subgrant under the grant U01HL105907 of the Department of Health and Human Services, Health Service, National Institutes of Health/National Heart, Lung and Blood Institute of the United States of 22.07.2011 for a multicenter, multinational clinical study “International Study of Comparative Health Effectiveness with Medical and Invasive Approaches” — ISCHEMIA.
About the Authors
L. L. Bershtein
I. I. Mechnikov North-Western State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
E. V. Zbyshevskaya
I. I. Mechnikov North-Western State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
V. E. Gumerova
I. I. Mechnikov North-Western State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541-619. doi:10.1093/eurheartj/ehu278.
2. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013.
3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394.
4. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.
5. Bershtein LL, Katamadze NO, Golovina AE, Sayganov SA. Revascularization in Stable Ischemic Heart Disease: Whether to Change the Approach? Kardiologiia.2016;56(4):66-74. (In Russ.) doi:10.18565/cardio.2016.4.66-74.
6. Stergiopoulos K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232-40. doi:10.1001/jamainternmed.2013.12855.
7. Rajkumar CA, Nijjer SS, Cole GD, et al. “Faith Healing” and “Subtraction Anxiety” in Unblinded Trials of Procedures: Lessons from DEFER and FAME-2 for End Points in the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2018;11:e004665. doi:10.1161/CIRCOUTCOMES.118.004665.
8. Xaplanteris P, Fournier S, Pijls NHJ, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379(3):250-9. doi:10.1056/NEJMoa1803538.
9. Stone GW, Hochman JS, Williams DO, et al. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia. The case for community equipoise. J Am Coll Cardiol 2016;67:81-99. doi:10.1016/j.jacc.2015.09.056.
10. Hochman JS, Reynolds HR, Bangalore S, et al. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology. 2019;4(3):273-86.
11. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 Mar 30. doi:10.1056/NEJMoa1915922.
12. ISCHEMIA Trial Results. https://www.ischemiatrial.org/system/files/attachments/ISCHEMIA%20MAIN%2012.03.19%20MASTER.pptx (01 April, 2020).
13. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:150316.
14. Grieve A. Adaptive designs: current status, future outlook. Trials. 2011; 12(Suppl 1): A137. doi:10.1186/1745-6215-12-s1-a1.
Review
For citations:
Bershtein L.L., Zbyshevskaya E.V., Gumerova V.E. Rationale for revascularization to improve prognosis in stable coronary artery disease: the data from ISCHEMIA trial. Russian Journal of Cardiology. 2020;25(8):3819. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3819
Views:
779
Email this article 